What is GRAIL?
GRAIL is at the forefront of revolutionizing cancer care through innovative early detection technologies. The company's flagship offering, the Galleri test, utilizes advanced methylation analysis and machine learning to detect multiple cancer types from a single blood draw by analyzing circulating cell-free DNA. This groundbreaking approach aims to significantly reduce cancer mortality rates by enabling detection at earlier, more treatable stages. GRAIL's mission is to transform cancer screening by making multi-cancer early detection (MCED) a standard part of routine healthcare, thereby changing the trajectory of cancer outcomes globally. The company's technology is designed for adoption by healthcare providers, oncologists, and individuals seeking proactive health management solutions.
How much funding has GRAIL raised?
GRAIL has raised a total of $2.1B across 6 funding rounds:
Series A
$100M
Series B
$900M
Series C
$300M
Unspecified
$125M
Series D
$390M
Stock/Share Issuance
$325M
Series A (2016): $100M with participation from GV, Bill Gates, Illumina, ARCH VENTURE PARTNERS, Bezos Expeditions, Biomatics Capital, Sutter Hill Ventures, and Longwood Fund
Series B (2017): $900M led by JJDC, ARCH Venture Partners, Merck, McKesson, Tencent HOldings Limited, Varian Medical Systems, Bristol-Myers Squibb, Celgene, and Amazon
Series C (2018): $300M supported by HuangPu River Capital, China Merchants Securities, Sequoia Capital China, Blue Pool Capital, WuXi NextCODE, ICBC International, Dimensions Capital, Ally Bridge Group, Hillhouse Capital Group, and CRF Investment
Unspecified (2019): $125M, investors not publicly disclosed
Series D (2020): $390M backed by Public Sector Pension Investment Board, Illumina, Inc., and CPP Investments
Stock/Share Issuance (2025): $325M with participation from Him & Her, Braidwell, Farallon, and Deep Track Capital
Key Investors in GRAIL
Sequoia Capital China
Sequoia Capital China is a prominent venture capital firm known for its investments in high-growth technology and healthcare companies across China. They actively partner with entrepreneurs to build market-leading businesses.
Illumina
Illumina, Inc. is a global leader in DNA sequencing and array-based technologies, providing critical tools and platforms for genomic analysis and research, including those essential for GRAIL's cancer detection technologies.
ARCH VENTURE PARTNERS
ARCH Venture Partners is a leading early-stage venture capital firm specializing in life sciences and advanced technology, often co-founding companies to commercialize groundbreaking innovations.
What's next for GRAIL?
With substantial capital infusions, GRAIL is strategically positioned to accelerate the widespread adoption of its early cancer detection technologies. The recent major strategic investment signals strong confidence from backers in GRAIL's mission and its potential to disrupt the traditional cancer screening landscape. Future endeavors will likely focus on expanding clinical validation, enhancing the Galleri test's capabilities, and forging deeper partnerships within the healthcare ecosystem to integrate this life-saving technology into standard clinical practice. Continued investment will also fuel advancements in AI and genomic analysis, further solidifying GRAIL's leadership in the burgeoning field of liquid biopsy and proactive cancer management.
